Healthcare Novartis plans to give away world's costliest therapy to some patients Updated : December 20, 2019 02:30 PM IST Zolgensma, with sales of $175 million through September, won US approval in May and has been touted as potentially curative for babies treated before symptoms begin. The programme applies to countries where the medicine is not yet approved for the rare genetic disorder affecting 1 in 10,000 live births. Roche's programme for risdiplam, the price of which has not been disclosed, would initially target patients with type 1 SMA, the most severe form. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.